Hook & thesis
Rocket Lab is no longer a niche launch contractor — it's squarely in the spotlight as the SpaceX IPO hysteria lifts the entire space ecosystem. With strong quarter-on-quarter revenue growth, a doubled backlog near $2.2 billion and a compact share float, Rocket Lab has the crosswinds needed for a tactical momentum trade.
My thesis is straightforward: buy RKLB at market while the SpaceX IPO narrative (and related ETF flows) is in full ascent. The technical picture shows fresh bullish momentum, short interest remains meaningful but manageable, and the company’s operational story (Neutron launches, Launch + Space Systems mix) gives the move an earnings/real-economy underpin. This is a swing trade targeted to capture the next leg higher as the SpaceX listing approaches and early post-IPO rotation favors smaller space names.
What Rocket Lab does and why the market should care
Rocket Lab builds and launches rockets and sells spacecraft and components. It operates two segments: Launch Services (dedicated and rideshare launches) and Space Systems (spacecraft engineering, manufacturing and on-orbit services). The business is capital-intensive but increasingly tied to recurring revenue through a growing backlog and satellite programs.
The market cares because the SpaceX IPO (roadshow beginning 06/04/2026 with expected pricing around 06/11/2026 and a public debut 06/12/2026) is acting like a sector-wide magnet. Investors rotate into smaller, high-beta space names ahead of and immediately after such watershed events. Rocket Lab is particularly sensitive to that rotation because it reported 64% Q1 revenue growth and a backlog reported at roughly $2.2 billion — figures that turn a headline-driven rally into something that can be defended on fundamentals.
Hard data that supports the trade
- Current price: $129.62.
- Market cap: roughly $72.6 billion (shares outstanding ~578.75 million).
- Enterprise value: about $71.47 billion; free cash flow last reported at -$316.3 million.
- Profitability metrics: EPS is negative (about -$0.32) and ROE is negative (~-8.06%), reflecting an early-stage, high-investment company.
- Valuation ratios look elevated: price-to-book near 31.9 and price-to-sales around 106.9. These numbers flag high expectations baked into the stock and justify a disciplined stop.
- Technicals: 10-day SMA is $124.01, 9-day EMA ~$122.06, RSI ~64.6 and MACD histogram is positive. That’s a momentum regime, not an overbought extreme.
- Short interest: ~33.3 million shares as of 04/30/2026 with days-to-cover around 1.43. Short volume has been elevated in recent sessions, which can amplify moves on positive flow.
Valuation framing
Take the valuation metrics at face value: a P/S north of 100 and P/B around 32 are extreme, and they reflect the market pricing in future growth, potential breakthrough launches (Neutron) and valuation re-rating tied to sector interest. In plain terms: the balance sheet and cash flow today don’t justify the current multiple. What does justify it is a narrative and the risk-adjusted prospect that Rocket Lab becomes a top-tier launch/space-systems integrator over the next several years. For this trade we’re not arguing the multiple is fair; we’re saying momentum + catalysts can move the price materially in the near-to-mid term, and that is the trade to exploit — with a strict stop because valuation leaves little margin for execution disappointment.
Catalysts to watch
- SpaceX IPO timeline: roadshow starting 06/04/2026 and pricing/IPO window around 06/11-06/12/2026 - this will increase retail and institutional interest in space names.
- Neutron program updates and any announced launch schedules or successful test milestones - operational clarity would materially re-rate sentiment.
- Quarterly results or updated backlog reads that confirm the reported doubled backlog (~$2.2 billion) and continued revenue acceleration (recent quarter showed ~64% growth).
- ETF flows into newly launched space ETFs and rebalancing ahead of the SpaceX IPO - these mechanical flows can produce outsized moves.
Trade plan (actionable)
Here’s a concise trade plan. The horizon below is mid-term: 45 trading days, chosen to span the immediate IPO window plus the typical post-IPO rotation period.
| Entry | Stop | Primary Target | Horizon |
|---|---|---|---|
| $129.62 | $110.00 | $170.00 | Mid term (45 trading days) |
Rationale: enter at the market (current liquidity is strong with average volumes in the 26–36M range). The stop at $110 limits downside to a defined level below the 20-day/50-day moving averages and undercuts a technical support band near prior short-term congestion. The target of $170 is a disciplined objective that captures a sizable re-rating without demanding sustained perfect execution — it implies a market cap in the high-$90s billion range if reached, which is plausible in a short-term sentiment-driven run.
How long should you hold?
Mid term (45 trading days). This time frame covers the lead-up to the SpaceX IPO and the immediate rotation window when smaller space names historically see pronounced moves. If price action gaps above $150 with volume and reduced short interest, consider tightening stops to protect gains. If the stock stalls below $120 on heavy volume, the stop at $110 protects capital.
Risks and counterarguments
- Valuation risk - P/S and P/B are extremely elevated. Any earnings or cash-flow disappointment could trigger a large drawdown because expectations are priced for perfection.
- Execution risk - Rocket Lab is still scaling Neutron and other programs; launch delays, failed tests or production bottlenecks would crush sentiment quickly.
- Market rotation risk - If the SpaceX IPO diverts capital to the IPO itself and into the big-name winners, smaller names could be sold into — a sentiment flip could erase gains.
- Macro & rates - Rising long-term yields or a risk-off environment (recall a prior day where 30-year yields spiked) can pull risk assets lower, irrespective of company-specific news.
- Short-squeeze dynamics - While short interest is not extreme on a days-to-cover basis, elevated short-volume means volatile intraday swings that can work against traders using wide stops or the wrong sizing.
Counterargument: critics will say Rocket Lab is priced for years of flawless execution and broad market support. That’s valid. If you believe the market will refocus on fundamentals and punish overvalued, negative-cash-flow companies quickly, then RKLB is a long-term avoid. This trade is explicitly not a long-term fundamental bet — it is a timing play around sector momentum. If you want a fundamental, multi-year investment, you should demand sustained profitability and lower multiples before committing for the long haul.
What would change my mind
I will abandon this trade and flip to neutral/bear if any of the following occur: an announced significant launch failure or major Neutron setback; quarterly results that miss backlog/revenue commentary or cut guidance; heavy distribution with volume above recent averages that pushes price below $110; or the SpaceX IPO triggers a rotation that visibly reallocates away from smaller space names. Conversely, a confirmed successful Neutron milestone, materially upgraded guidance or a demonstrable widening of institutional ownership would make me more positive and could justify raising the target.
Conclusion
Rocket Lab sits at a unique intersection: real operational progress (backlog growth, revenue acceleration) and a market environment that is primed to re-rate space stocks as SpaceX goes public. That combination creates a defined-risk, high-upside swing trade. Enter at $129.62 with a stop at $110 and a primary target of $170 over roughly 45 trading days. Be disciplined: the tailwinds are strong, but the valuation leaves little margin for execution error.
Trade plan summary: Long RKLB at $129.62, stop $110.00, target $170.00, horizon: mid term (45 trading days).